An epidemiological study of the cardiovascular health and thrombotic risk profiles of patients with myeloproliferative neoplasms in primary care across the United Kingdom
Last Updated: Tuesday, July 6, 2021
Retrospective data presented during the 2021 European Hematology Association Virtual Congress suggests that 11.1% to 22.1% of MPN patients in the United Kingdom did not receive the appropriate medications for the management of comorbidities associated with thrombotic risk, including hypertension, dyslipidemia, and diabetes.
Advertisement
News & Literature Highlights